Michael Dasilva, MD
Ophthalmology · Omaha, NENPI 1992237903
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,616 of the $2,548 with a category attached, or 63.4%. 12 manufacturers reported payments, led by US Retina LLC at 36.6% of the total. Reporting peaked in 2022 at $1,188 and has fallen 59.0% since, to $487 in 2025.
Across 56 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$932
- Alcon$690
- AbbVie$234
- Bausch & Lomb Americas Inc.$190
- NEW World Medical,inc.$161
- Biotissue Holdings Inc.$129
- plus $211 from 6 others
What the payments were for
- Food & beverage$1,61663%
- Ownership interest$93237%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 2 | $932 |
| Alcon | 10 | $690 |
| AbbVie | 16 | $234 |
| Bausch & Lomb Americas Inc. | 10 | $190 |
| NEW World Medical,inc. | 4 | $161 |
| Biotissue Holdings Inc. | 3 | $129 |
| Astellas Pharma US Inc | 3 | $71 |
| Oyster Point Pharma, Inc. | 3 | $53 |
| Glaukos Corporation | 2 | $33 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Topcon Healthcare, Inc. | 1 | $18 |
| Rxsight Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,548 in reported general payments places this provider in the 80th percentile of 105 ophthalmology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 24 | $403 |
| Prednisolone Acetate | 11 | $357 |
| Tamsulosin Hcl | 12 | $282 |
| Sertraline Hcl | 12 | $236 |
| Latanoprost | 28 | $193 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Omaha
- Brandon BaartmanOmaha$226K
- Ronald KruegerOmaha$224K
- Lorraine ProvencherOmaha$220K
- Lance KuglerOmaha$41K
- Rao ChunduryOmaha$14K
- Shane HavensOmaha$6K
- Brandon MenkeOmaha$6K
- Sao LiuOmaha$5K
- Michael HalstedOmaha$4K
- Thomas HejkalOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.